

DETAILED ACTION

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Michael R. Wesolowski, Reg. No. 50,944, on 23 April 2009.

The application has been amended as follows:

2. IN THE CLAIMS:

Cancel claims 1-12.

Please replace Claim 13 with the following Claim 13

Claim 13. An inhibitor of mycobacterial serine/threonine protein kinase G (PknG), said inhibitor comprising the compound: 2-(cyclopropanecarbonyl-amino)-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid amine;
or a pharmaceutically acceptable salt thereof.

Claim 14. (Currently amended) A pharmaceutical composition useful for treating mycobacterial infections, said pharmaceutical composition comprising ~~at least one~~ the inhibitor of a mycobacterial serine/threonine protein kinase G (PknG) according to Claim 13 and a pharmaceutically acceptable carrier, excipient or diluent

Art Unit: 1645

Cancel claims 15-23.

Rejections Moot or Withdrawn

3. The rejection of claims 13 and 14 under 35 U.S.C., 112, first paragraph, scope of enablement, is withdrawn in light of the amendment of the claims.
4. The rejection of claim 15 under 35 U.S.C., 112, first paragraph, scope of enablement, is moot in light of the cancellation of the claim.
5. The rejection of claims 13 and 14 under 35 U.S.C., 112, second paragraph, indefiniteness, is withdrawn in light of the amendment of the claims.
6. The rejection of claim 15 under 35 U.S.C., 112, second paragraph, indefiniteness, is moot in light of the cancellation of the claim.

Conclusion

7. Claims 13 and 14 are allowed.
8. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Wednesday from 9:00 AM to 7:30 PM EST. Thursday is the examiner's work at home day.

If attempts to reach the Examiner by telephone are unsuccessful, please contact the Examiner's Supervisor, Robert B. Mondesi (571)272-0956.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Art Unit: 1645

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rodney P. Swartz, Ph.D./

Primary Examiner, Art Unit 1645

May 1, 2009